We have come a long way from our last discussion about the bispecific antibody landscape going into the ASH20 meeting, with the current update on the field barely including any of those established agents, such is the pace of progress in less than a year!
Of course, part of difference lies in the old liquid versus solid tumour settings, where different tools or targets are needed for each one.
The good news is there are a lot of new players to look at, both private and public, emerging biotech and established pharma companies.
Some of the evolving trends which emerged from our latest analysis surprised even the seasoned observers at BSB, which is no bad thing at all.
So what’s in store from our latest in-depth review going into SITC 2021?